RemeGen Co., Ltd.

Research RemeGen Co., Ltd. (9995.HK) on Bullrun: market cap HKD 39.25B, P/E 5.7. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker9995.HK
ExchangeHK
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyHKD
Market capHKD 39.25B
P/E5.7
Financial periodFY2025
RevenueCNY 3.24B
Revenue growth89.5%
Net incomeCNY 709.65M
Free cash flow-CNY 147.66M
Gross margin86.9%

Valuation Snapshot

latest market cap is HKD 39.25B; P/E is 5.7.

Peer valuation comparison

Latest P/E is 5.67x versus a Healthcare sector median of 21.69x (73.9% below).

Latest P/E is 5.67x versus a China median of 16.26x (65.1% below).

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CNY 3.24B	CNY 709.65M	-CNY 147.66M	86.9%	n/a	CNY 1.15B	CNY 2.20B	CNY 3.61B
FY2024	CNY 1.71B	-CNY 1.47B	-CNY 1.44B	80.0%	-2.73	CNY 759.53M	CNY 2.67B	CNY 1.99B
FY2023	CNY 1.08B	-CNY 1.51B	-CNY 2.35B	76.5%	-2.8	CNY 726.55M	CNY 1.26B	CNY 3.44B
FY2022	CNY 767.78M	-CNY 998.83M	-CNY 2.02B	64.8%	-1.88	CNY 2.07B	CNY 165.04M	CNY 4.98B
FY2021	n/a	n/a	n/a	n/a	0.57	n/a	n/a	n/a

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	HKD 39.25B	5.7	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About RemeGen Co., Ltd.

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis;

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Shanghai RAAS Blood Products Co Ltd (002252.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK)